HA-966 (1-hydroxy-3-aminopyrrolidone-2) selectively reduces N-methyl-D-aspartate (NMDA)-mediated brain damage.

Abstract

The neuroprotective effects of the strychnine-insensitive glycine receptor antagonist, HA-966, against N-methyl-D-aspartate (NMDA)- and quisqualate (QA)-mediated brain injury were determined in perinatal rats. Postnatal day (PND) 7 rats received intrastriatal injections of NMDA (25 nmol) or QA (100 nmol) and then were administered intraperitoneal (i.p.) injections of varying doses of HA-966 or vehicle 15 min later. Animals were sacrificed 5 days later and the degree of brain injury was calculated by comparison of the weights of injected and contralateral cerebral hemispheres. HA-966 selectively reduced the degree of NMDA-mediated brain injury in a dose-dependent manner. However, HA-966 did not attenuate QA-mediated brain injury.

• Authors: J W McDonald, J Uckele, F S Silverstein, M V Johnston
• Journal: Neuroscience letters (Neurosci Lett) Vol. 104 Issue 1-2 Pg. 167-70 (Sep 25 1989) ISSN: 0304-3940 [Print] Ireland
• PMID: 2682393 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Oxadiazoles
• Pyrrolidinones
• Aspartic Acid
• N-Methylaspartate
• Quisqualic Acid
• 1-hydroxy-3-amino-2-pyrrolidone

Topics

• Animals
• Animals, Newborn
• Aspartic Acid (administration & dosage, pharmacology)
• Brain Diseases (chemically induced, prevention & control)
• Corpus Striatum (drug effects)
• N-Methylaspartate
• Oxadiazoles (administration & dosage, pharmacology)
• Pyrrolidinones (therapeutic use)
• Quisqualic Acid
• Rats
• Rats, Inbred Strains